South San Francisco, CA based CytomX Therapeutics [CTMX], a longstanding client of Occam Global’s, has strengthened its leadership team with the appointment of Jeff Landau as SVP, Head of Strategy and Chief Business Officer. CytomX is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies. The company is developing a novel class of investigational conditionally activated therapeutics, based on its Probody® technology platform, for the treatment of cancer. CytomX has strategic drug discovery and development collaborations with AbbVie, Amgen, Astellas, and Bristol Myers Squibb.
Jeff Landau has over 20 years of biopharmaceutical experience in corporate development, corporate strategy, and new product strategy/planning. Most recently, he was SVP Corporate Development, Commercial and New Product Strategy at Catalyst Biosciences, Inc., where he was responsible for partnering, license and acquisition, corporate strategy, pipeline and new product planning, and alliance and project management. Prior to joining Catalyst, Jeff held corporate development and global product and pipeline strategy roles of increasing responsibility at Threshold Pharmaceuticals and Onyx Pharmaceuticals (acquired by Amgen). Jeff holds a BS in Biochemistry/Biotechnology from Virginia Polytechnic Institute and an MBA from Stanford Graduate School of Business.
Recently, Occam also placed Chau Cheng, PhD as VP, Investor Relations & Corporate Communications at CytomX. Previously, Chau led investor relations at Immunomedics, Inc. for over 15 years until the company’s acquisition by Gilead Sciences for $21B.